TW201143761A - Tablet formulation of ezatiostat - Google Patents

Tablet formulation of ezatiostat Download PDF

Info

Publication number
TW201143761A
TW201143761A TW100111502A TW100111502A TW201143761A TW 201143761 A TW201143761 A TW 201143761A TW 100111502 A TW100111502 A TW 100111502A TW 100111502 A TW100111502 A TW 100111502A TW 201143761 A TW201143761 A TW 201143761A
Authority
TW
Taiwan
Prior art keywords
amount
excipient
lozenge
tablet
hydrochloride
Prior art date
Application number
TW100111502A
Other languages
English (en)
Chinese (zh)
Inventor
Robert T Lum
Stephan D Parent
Chun-Sheng Qiao
Steven R Schow
Original Assignee
Telik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telik Inc filed Critical Telik Inc
Publication of TW201143761A publication Critical patent/TW201143761A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW100111502A 2010-06-07 2011-04-01 Tablet formulation of ezatiostat TW201143761A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35237710P 2010-06-07 2010-06-07

Publications (1)

Publication Number Publication Date
TW201143761A true TW201143761A (en) 2011-12-16

Family

ID=42829329

Family Applications (1)

Application Number Title Priority Date Filing Date
TW100111502A TW201143761A (en) 2010-06-07 2011-04-01 Tablet formulation of ezatiostat

Country Status (8)

Country Link
US (2) US20110300215A1 (enExample)
EP (1) EP2576591A2 (enExample)
JP (1) JP2013528213A (enExample)
CN (1) CN102917694A (enExample)
AR (1) AR080895A1 (enExample)
CA (1) CA2797458A1 (enExample)
TW (1) TW201143761A (enExample)
WO (1) WO2011156045A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012151051A1 (en) * 2011-05-03 2012-11-08 Telik, Inc. Excipient compatibility with ezatiostat
US20130035389A1 (en) 2011-08-05 2013-02-07 Telik, Inc. Methods for treating myelodysplastic syndrome with ezatiostat
US10156885B2 (en) 2014-04-07 2018-12-18 Avago Technologies International Sales Pte. Limited Network energy consumption reduction
WO2016117927A1 (ko) 2015-01-20 2016-07-28 주식회사 한림포스텍 무선 전력 전송 장치 및 이의 전송 전력 제어 방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599903A (en) 1992-04-03 1997-02-04 Terrapin Technologies, Inc. Glutathione analogs and paralog panels comprising glutathione mimics
US5114003A (en) * 1991-03-28 1992-05-19 E. I. Du Pont De Nemours And Company Tablet vial with desiccant in bottom
US5786336A (en) 1991-04-29 1998-07-28 Terrapin Technologies, Inc. Target-selective protocols based on mimics
US5955432A (en) * 1992-04-03 1999-09-21 Terrapin Technologies, Inc. Metabolic effects of certain glutathione analogs
US5965164A (en) 1994-10-28 1999-10-12 Fuisz Technologies Ltd. Recipient-dosage delivery system
US6627732B1 (en) * 1998-04-16 2003-09-30 Teijin Limited Glutathione derivatives and their dosage forms
WO2002088664A2 (en) * 2001-04-26 2002-11-07 Bristol-Myers Squibb Company Control of compactability through crystallization
US7029695B2 (en) 2001-07-10 2006-04-18 Telik, Inc. Therapeutic compositions containing glutathione analogs
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
WO2005065639A2 (en) 2003-11-21 2005-07-21 Torrent Pharmaceuticals Limited Novel pharmaceutical compositions
CN101133020A (zh) * 2004-12-03 2008-02-27 特瓦制药工业有限公司 依泽替米贝多晶型
HRP20090128T3 (hr) * 2005-01-06 2009-04-30 Telik Inc. Tripeptid i tetrapeptid tioeteri
EP1880722B1 (en) 2006-07-19 2010-03-17 Tabuk Pharmaceutical Manufacturing Co. Pharmaceutical compositions of ciprofloxacin
EP2125715A2 (en) * 2007-01-24 2009-12-02 Krka Process for the preparation of ezetimibe and derivatives thereof
EP2114380A1 (en) 2007-01-25 2009-11-11 Panacea Biotec Ltd. Modified release pharmaceutical composition and a process of making the same
MX2010001711A (es) 2007-08-13 2010-03-11 Panacea Biotec Ltd Composiciones de liberacion extendida que comprenden micofenolato sodico y procedimientos de las mismas.
AR068745A1 (es) 2007-10-08 2009-12-02 Panacea Biotec Ltd Una composicion en forma de dosificacion farmaceutica oral de unidad de alta dosis de micofenolato sodico, metodo para utilizar dicha composicion y sus usos

Also Published As

Publication number Publication date
WO2011156045A2 (en) 2011-12-15
US20120021054A1 (en) 2012-01-26
CA2797458A1 (en) 2011-12-15
US8361971B2 (en) 2013-01-29
EP2576591A2 (en) 2013-04-10
JP2013528213A (ja) 2013-07-08
US20110300215A1 (en) 2011-12-08
AR080895A1 (es) 2012-05-16
CN102917694A (zh) 2013-02-06
WO2011156045A3 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
JP6034789B2 (ja) 結晶性ナロキソール−ｐｅｇ接合体
TW200944508A (en) Novel solid forms of bendamustine hydrochloride
EA018704B1 (ru) НОВЫЕ ФОРМЫ МЕТИЛОВОГО ЭФИРА 2-ЦИАНО-3,12-ДИОКСООЛЕАН-1,9(11)-ДИЕН-28-ОВОЙ КИСЛОТЫ (CDDO-Me)
JP2016513704A (ja) チロシンキナーゼ阻害薬の結晶形態物及びその塩
Salazar-Rojas et al. Preparation and characterization of a new solid form of praziquantel, an essential anthelmintic drug. Praziquantel racemic monohydrate
IL290428A (en) Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof
TW201143761A (en) Tablet formulation of ezatiostat
Liu et al. Preparation, Characterization and Evaluation of Nintedanib Amorphous Solid Dispersions with Enhanced Oral Bioavailability
US20120165260A2 (en) Crystalline ezatiostat hydrochloride ansolvate
US9211290B2 (en) Solid dispersions of amorphous paroxetine mesylate
TW202535400A (zh) 整合素抑制劑及其用途
RU2822220C2 (ru) Фармацевтические композиции для лечения муковисцидоза
KR20110115607A (ko) 6-옥소-6,7,8,9,10,11-헥사히드로시클로헵타(ｃ)크로멘-3-일 술파메이트 및 그의 다형체를 함유하는 고체 제약 조성물
WO2018130226A1 (zh) 利奥西呱的新晶型及其制备方法和用途